Avtozma is the 12th biosimilar from Celltrion to receive approval from the EC. Credit: © CELLTRION INC. All Rights Reserved.

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab). The approval allows Avtozma ...

INCHEON, SOUTH KOREA – Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab).

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been ...